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Abstract
Background: Low molecular weight (LMW) heparins are used for anticoagulation during hemodialysis (HD).
Studies in animals have shown that LMW-heparins release lipoprotein lipase (LPL) as efficiently as unfractionated
(UF) heparin, but are less able to retard hepatic uptake of the lipase. This raises a concern that the LPL system may
become exhausted by LMW-heparin in patients on HD. We have explored this in the setting of clinical HD.
Methods: Twenty patients on chronic hemodialysis were switched from a primed infusion of UF-heparin to a
single bolus of tinzaparin. There were long term follow up of variables for the estimation of dialysis efficacy as well
as of the LPL release during dialysis and the subsequent impact on the triglycerides.
Results: The LPL activity in blood was higher on tinzaparin at 40 but lower at 180 minutes during HD. These
values did not change during the 6 month study period. There were significant correlations between the LPL
activities in individual patients at the beginning and end of the 6 month study period and between the activities
on UF-heparin and on tinzaparin, indicating that tissue LPL was not being exhausted. Triglycerides were higher
during the HD-session with tinzaparin than UF-heparin. The plasma lipid/lipoprotein levels did not change during
the 6 month study period, nor during a 2-year follow up after the switch from UF-heparin to tinzaparin. Urea
reduction rate and Kt/V were reduced by 4 and 7% after 6 months with tinzaparin.
Conclusion: Our data demonstrate that repeated HD with UF-heparin or tinzaparin does not exhaust the LPL-
system.
Background
During hemodialysis (HD) the patient must receive
anticoagulation. According to the traditional protocol
this is given as a primed infusion of UF-heparin. A
newer approach, that has practical advantages, is to give
a single bolus of LMW-heparin [1,2]. This is possible
since the LMW preparations are cleared more slowly
from blood; half-lives of 2 - 6 hours have been reported
compared to only about 1 h for UF-heparin. Further-
more, whereas the pharmacodynamics of UF-heparins
shows large differences between patients, the elimination
kinetics for LMW-heparins is more predictable and
therefore safe in most situations. One consideration
when comparing the two preparations is that heparin
releases the enzyme lipoprotein lipase (LPL) from its
binding sites at the vascular endothelium into the circu-
lating blood [3]. This leads to accelerated degradation of
the enzyme which is taken up from blood into the liver,
and this in turn leads to a period of relative LPL deple-
tion during which the metabolism of triglyceride
(TG)-rich lipoproteins is slowed down [4,5]. Studies in
experimental animals [4] and in human subjects [6]
indicate that this is more marked with LMW-heparins
compared to UF-heparin. The local clinical HD unit
recently decided to switch from UF-heparin to tinza-
parin (one of the LMW-heparins that is commonly used
for HD [7-9]). In conjunction with this, we decided to
carry out a quality assurance investigation with empha-
s i so ne f f e c t so ft h ed i f f e r e n th e p a r i n so nt h eL P L
system and clinical variables in the setting of chronic
HD. A major question was if the LPL system may
become exhausted by LMW-heparin in patients on HD. * Correspondence: bernd.stegmayr@medicin.umu.se
2Department of Internal Medicine, University Hospital, SE-90185, Umeå,
Sweden
Full list of author information is available at the end of the article
Mahmood et al. BMC Nephrology 2010, 11:33
http://www.biomedcentral.com/1471-2369/11/33
© 2010 Mahmood et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.Methods
Patients and study protocol
The study included twenty patients who had been on
chronic HD for at least 3 months (range 3-72 months).
Baseline data are given in table 1. The reason for dialysis
was diabetes mellitus in six patients, vasculitis in four,
interstitial nephritis in three, polycystic kidney disease in
two, glomerulonephritis in two, and one each with
nephrosclerosis, post renal obstructive problems, and
myeloma associated amyloidosis. Eleven of the patients
were on statin medication, with unchanged dose,
throughout the study. Before the study all patients were
on dialysis with primed infusion of UF-heparin (Leo
Pharma, Ballerup, Denmark) as anticoagulant (table 2).
Data were not obtained during the entire study period
for four subjects; two died (one due to progressive mye-
loma, one due to congestive heart failure); two received
renal transplants. The Regional Ethical Review Board in
Umeå, Sweden, approved the study. Informed consent
was obtained from all patients.
The design of the study is illustrated in figure 1. After
randomization six men and four women were switched
to tinzaparin (Leo Pharma, Ballerup, Denmark). After a
run in period they were followed for 6 months. Ten
others (six men and four women) continued on UF-
heparin for 6 months and then switched to tinzaparin
and were followed for 6 months.
UF-heparin was given as a bolus of approximately 50
units/kg body weight at the start of HD followed by a
continuous infusion of 800-1200 units/hour. The doses
were adjusted with the aim to keep the activated partial
thromboplastin time within 40-90 seconds until the last
45 min of dialysis. Then, the heparin infusion was
stopped for those who had peripheral access, to allow
sufficient coagulation upon stop of dialysis. For patients
with a central dialysis catheter the infusion of heparin
continued until the end of HD.
Tinzaparin (Leo Pharma, Ballerup, Denmark) was
given as a bolus of 4500 anti-Xa units. After switching
f r o mh e p a r i nar u ni np e r i o dw a sa l l o w e dt oa d j u s tt h e
tinzaparin dose, which usually took 2-4 weeks. If clot-
ting was noticed (by vision) in the system or if there
was a bleeding tendency, the dose was changed in steps
of 500 units, according to the manufacturer’s
recommendations.
The dialysate contained conventional electrolytes
(Meda, Solna, Sweden) and a final concentration of 5
mmol/l glucose. The dialyzers were from Fresenius
Medical Care (Hechingen, Germany; F8HPS and FX80,
one and four patients, respectively) and Gambro (Lund,
Sweden; PF140 H and PF210 H, nine and six patients,
respectively). Each patient used the same type of dialyzer
for the whole series (no reuse).
Dry weight of the patient was followed throughout the
study. This is the weight that a patient with normal
urine production would have despite fluid intake. In
patients with loss of urine output, water is retained
between dialyses and weight increases (inter dialysis
weight gain).
The body weight, the serum albumin and urea con-
centrations were stable over the observation period,
indicating that the patients were not malnourished.
Blood sampling and analytical procedures
The patients were asked to fast overnight if dialysis
started in the morning. However, several refused fasting.
Those who refused to fast (i.e. diabetic patients) were
told to keep a low fat diet with a cup of tea and only
carbohydrates for breakfast and to keep the same regime
of diet for all dialyses included in the study. This was
accepted by them.
After approximately 60 minutes of dialysis they
received a light meal (sandwiches).
Blood samples before dialysis were obtained directly
from the AV fistula or from the arterial line of the cen-
tral dialysis catheter. Blood samples at the end of dialy-
sis were drawn according to the Swedish guidelines for
blood sampling after dialyses. This means that after the
end of HD the dialysate flow is stopped and the blood
Table 1 Baseline data*
Variables Mean (SD) Median
Age, years 64 (2.8) 64
Dry weight, kg 77.6 (18.3) 73.3
Hemoglobin, g/l 121 (4.7) 120
Albumin, g/l 37 (4.2) 38
Urea, mmol/l 21 (5.0) 22
Creatinine, μmol/l 683 (252) 625
total Cholesterol, mmol/l 4.0 (1.0) 4.1
LDL-cholesterol, mmol/l 1.9 (0.7) 1.9
HAL-cholesterol, mmol/l 1.2 (0.4) 1.1
Triglycerides, mmol/l 2.0 (1.1) 1.6
* The blood and serum values (± 1 standard deviation, SD) were obtained
before dialysis at the last day of routine UF-heparin treatment and before
start of the tinzaparin period (figure 1).
Table 2 Data for Kt/V, urea reduction rate, ultrafiltration
volume and UF-heparin dose during the last performance
of UF-heparin HD before start of the tinzaparin period
Variables Mean (SD) Median
Kt/V 1.46 (0.32) 1.47
Urea reduction by dialysis, % 72.8 (5.5) 72.5
Ultrafiltration volume, liters 1.50 (1.10) 1.55
Ultrafiltration, % of body weight 2.1 (1.9) 2.0
UF-heparin total dose, Units 7573 (1533) 7500
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Page 2 of 8flow is reduced to 100 ml/min for 15 seconds before the
blood pump is stopped and disconnected from the
patient. Most of the blood that resides in the tubes is
returned to the patient. Blood samples were taken from
the arterial needle at the site of the AV fistula or AV
graft or drawn from the arterial part of the central dialy-
sis catheter. When samples were taken during dialysis,
they were drawn on the arterial side of the tubing set,
before the dialyzer. This was the same in all series.
Urea was analyzed in blood samples drawn after the
end of HD, to calculate urea reduction rate and Kt/V
(according to the second generation formula by Daugir-
das, considering the effect of the extent of ultrafiltration
[10]). These parameters were used as measures for the
weekly dose of dialysis to decide if the dialysis was effi-
cient enough. An insufficient value would cause a pre-
scription of more extensive dialysis. During this study
such changes were not necessary. Urea reduction rate
a n dK t / Vw e r ea l s ou s e da si n d i r e c tm a r k e r so ff u n c -
tional surface area of the dialyzer. If the surface was
changed by clotting, the efficacy of dialysis would be
reduced since the other variables were kept constant
(blood flow, dialysate flow, dialyzer, dialysis time). In
addition, the Transonic Flow-QC Hemodialysis Monitor
(HD01 Plus, Transonic systems inc., NY, USA) was used
to measure the blood volume of the dialyzer before and
after dialysis, to estimate the extent of clotting that
could appear during hemodialysis. A specific software
for such calculations was provided by the manufacturer.
Blood samples were drawn during the dialyses (40, 180
and 210 min) for analysis of LPL and blood lipids. At
the end of HD a sample was drawn for assay of Factor
Xa.
LPL activity in the blood samples was measured as
previously described after hepatic lipase had been
removed by immunoadsorption [6].
Retrospectively we compared the serum concentra-
tions of TG, total cholesterol, LDL, HDL, albumin and
CRP during one year prior to the study and 1 1/2-2
years after the study. In three patients the post-study
period was shortened due to transplantation. Four other
patients died within one year after the end of the study
period.
Statistical analyses
Results are expressed as mean ± s.e.m. (standard error
of mean). Statistical analysis was performed with SPSS
software, version 11 (SPSS inc. Chicago, Illinois, USA).
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Figure 1 Flow chart of the study.
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Page 3 of 8Paired non parametric (Wilcoxon) analyses were used to
compare values measured for the same individual (n =
20 pairs). Non-paired statistics (Mann Whitney) were
used to compare groups with each other. For analyses of
correlation the Pearson test was used. A two tailed p-
value of < 0.05 was considered as significant.
Results
UF-heparin/Tinzaparin doses
The median UF-heparin bolus was 2500 units (range
2000-4500) corresponding to 37 units/kg body weight.
This was followed by a continuous infusion of a median
of 1000 units/hour (range 200-1600 units/h), giving a
total dose of 7500 units/dialysis (median, range 5200-
10500). The change from UF-heparin to tinzaparin
needed 0-4 weeks (based on visual evaluation of clotting
or bleeding). Nineteen of the patients needed only one
bolus of tinzaparin while one patient needed a second
bolus (2000 units) after 180 min of dialysis (total dose
14000 units). Values at 210 min for this patient were
excluded.
The median tinzaparin dose was 6000 units (range
3500-14000). This is in line with the dose of 75 anti-Xa
units/kg body weight used in a detailed study of the
pharmacokinetics of tinzaparin in patients undergoing
HD [11-13].
The mean anti-Xa activity of the patients given tinza-
parin was 0.26 U/L (± 0.05, range 0.07-0.78). The dialy-
zers remained subjectively patent by visual evaluation,
during all dialyses. No patient had side effects due to
anticoagulation, besides limited and expected local
bleeding at the access after the end of the dialysis.
Evaluation of dialysis efficacy
To estimate if clotting reduced the dialyzer volume,
Transonic measurements were made at the start and at
the end of dialysis. This showed that dialyzer volumes
were not significantly reduced (median 1%, range -16 to
+ 10%). There were no differences in this regard between
the two anticoagulants or between the dialyzers used.
There were also no differences in dry weight, serum
creatinine, urea, albumin, change in filter area (mea-
sured by Transonic) or Kt/V comparing the two parallel
groups (figure 1) that received UF-heparin or tinzaparin
during the first 6 month period. Neither was there a dif-
ference when comparing, by paired statistics, each indi-
vidual patient when on UF-heparin (last dose before
s w i t c h )o rt i n z a p a r i n( f i r s td o s ew h e nc o n s i d e r e di n
steady state, after 2-4 w). The start values for Kt/V were
1.43 and 1.46 for the UF-heparin and tinzaparin mea-
surements, respectively.
When comparing data during the 6 months tinzaparin
follow-up period, urea reduction rate and Kt/V were
l o w e r e d( p<0 . 0 2 )b y4 %a n d7 %a t6m o n t h s( b u tn o t
at 3 months), indicating a slight reduction in dialysis
efficacy. There was no such reduction of these variables
in the group that were studied for 6 month with UF-
heparin, before switch to tinzaparin (figure 1).
Lipoprotein lipase activity
LPL activity in plasma was high at 40 min after injection
of UF-heparin or tinzaparin and then decreased to much
lower values at 180 min and 210 min (figure 2). No sig-
nificant change occurred in the LPL activities over the 6
month study period whether they were tested as values
at single times or as area under the curve. There was a
strong correlation (r = 0.76, p < 0.01) between the peak
LPL activity (40 min value) measured at the start of the
tinzaparin period and after 6 months on tinzaparin (fig-
ure 3). Likewise there was a strong correlation between
the peak LPL activities after tinzaparin and after heparin
(r = 0.55, p < 0.02, figure 4).
The LPL activity at 40 min was somewhat higher after
tinzaparin than after UF-heparin (figure 2 p < 0.05)
whereas LPL activities after 180 and 210 min were
lower using tinzaparin (figure 2 p < 0.001 at both times).
To estimate the amount of LPL remaining in the tis-
sues after HD with tinzaparin, a bolus of UF-heparin
was given at 180 min to 11 patients (figure 5). Thirty
min later, LPL activity had increased by 18 ± 8.0 U/l (p
< 0.01). This increase was similar to that noted in a pre-
vious study with dalteparin as anticoagulant (19.5 ± 6.5
U/l) [5,14].
Lipids
No significant changes occurred, neither during the
study period using UF-heparin (figure 1), nor when all
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Figure 2 Median LPL activities in plasma during dialysis with
UF-heparin or tinzaparin. UF-heparin - open circles and filled lines
(at the points in time denoted “End heparin” in Figure 1); tinzaparin
at start (i.e. after the run-in period) - open squares and hatched
lines; tinzaparin 3 months - grey squares and hatched lines;
tinzaparin 6 months - filled squares, dotted lines.
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Page 4 of 8patients were switched to tinzaparin, in predialysis
values for plasma TG, total cholesterol, LDL- or HDL-
cholesterol, albumin or CRP. To further explore this we
collected all data from the records for a period from
one year before to 1.5 - 2 years after the study. Since
t h e r ew a saw i d er a n g eo fv a l u e sa m o n gi n d i v i d u a l
patients we calculated the ratio of the value while on
tinzaparin divided by the value while on heparin. This
returned the following ratios: TG 0.98 ± 0.09 (mean ±
SEM); total cholesterol 0.97 ± 0.05; LDL cholesterol
0.94 ± 0.08; and HDL-cholesterol 1.00 ± 0.04. None of
these ratios revealed any statistically significant change.
The ratio for CRP was 1.45 ± 0.26 (p = 0.43).
During the HD and after injection of UF-heparin or
tinzaparin, plasma TG decreased at 40 min (p < 0.001),
and then rose again to reach values at the end of the
dialysis (180 and 210 min) similar to those before UF-
heparin/tinzaparin (figure 6). The TG values did not
decrease as much at 40 min and were then higher after
tinzaparin than after UF-heparin at 180 and 210 min
(p = 0.05, p < 0.01 and p < 0.01, respectively).
Discussion
The main conclusion from this study is that long term
repeated administrations either UF-heparin or tinzaparin
during chronic hemodialysis does not cause exhaustion
of the LPL production.
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Figure 5 Test of the amount of LPL available in the system at
40 minutes and during the end of a HD with tinzaparin.A
bolus of UF-heparin (50 units/kg body weight, intravenously) was
given after 180 min of HD with tinzaparin to evaluate the extent of
residual LPL on the endothelial sites. Eleven of the patients
accepted to participate in this second step of investigation. Blood
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the reduced time and material needed to prepare and
administer tinzaparin instead of UF-heparin. However,
we found a slight reduction in dialysis efficacy with tin-
z a p a r i na t6m o n t h sb u tn o tw i t hU F - h e p a r i n ,w h e n
comparing the values for the urea reduction rate and
the Kt/V from start to the value obtained after 6 months
with respective anticoagulant. We found no significant
difference using the Transonic method (as a measure
for patent capillaries of the dialyzer). The variation in
data was larger with the Transonic method, and there-
fore the precision was lower than for urea reduction
rate and Kt/V. Taken together these data indicate that
the pore size may have decreased somewhat when using
tinzaparin, perhaps by formation of a fibrin layer on the
dialyzer surface. Our overall conclusion is, however, that
there were no marked differences between the two
anticoagulation regimes in their effect on the function
of the dialyzers. The patients did not show any obvious
changes in bleeding or clotting tendency, comparing the
two heparin preparations. Our observations on the effi-
cacy and safety of tinzaparin as anticoagulant in HD are
in line with earlier studies [1,7-9,11-13,15]. Notable is,
that in one of these studies the extent of clotting was
increased in the venous bubble traps with tinzaparin
[13], indicating an increased tendency of clotting.
In some studies the plasma LPL activity has been found
to be lower after injection of LMW-heparin than after
UF-heparin and this has led to the conclusion that
LMW-heparin has a lesser impact on the LPL system.
This is not correct. Studies in experimental animals have
shown that LMW-heparins are at least as effective as UF-
heparin to release the lipase into blood, but less effective
in retarding hepatic uptake of the lipase [4]. When rat
hearts were perfused by a single pass of medium, heparin
decasaccharides (a molecular size that corresponds to the
lower end of LMW-heparin preparations) released LPL
into the medium more efficiently than UF-heparin [16].
In contrast, the decasaccharides had a poor ability to
retard hepatic clearance of the lipase. Interpretation of
time curves of lipase activity in blood after heparin injec-
tion is complex. In addition to the ability of the particular
heparin preparation to release the lipase and to retain it
in the circulating blood one needs to consider the num-
ber of heparin molecules injected (rather than coagula-
tion-based units), their size and sulfation, as well as the
rate at which different heparin molecules are cleared
(longer heparin chains are cleared more rapidly). In the
present study plasma LPL activity tended to be somewhat
higher 40 min after tinzaparin than after UF-heparin.
This presumably reflects that a larger number of heparin
molecules were injected with the LMW preparation and
that these molecules efficiently released the lipase. It is of
interest to note that there was a strong correlation
between the LPL activites 40m i na f t e rt i n z a p a r i na n d
after heparin in individual subjects. After 180 min the
plasma LPL activity was lower with tinzaparin, presum-
ably reflecting a lesser ability of the shorter heparin
chains to retain the enzyme in the circulating blood. In
an earlier study by Näsström et al. the peak LPL activity
after dalteparin was only about one-third of that with
UF-heparin. A difference between the studies is the use
of tinzaparin instead of dalteparin that was used in the
study by Näsström et al. [6]. Tinzaparin is known to have
the largest mean molecular weight of all LMW-heparins
[2] and is therefore structurally closer to UF-heparin.
This probably explains the different patterns of plasma
LPL activity during HD with dalteparin or tinzaparin.
The effect of heparin injection on lipoprotein metabo-
lism is biphasic [3]. Initially there is accelerated lipolysis.
The interpretation is that LPL has more ready access to
substrate lipoproteins when it is in the circulating blood.
In the basal state the lipase is at binding sites at the vas-
cular endothelium [17], whereas most of the lipopro-
teins are in the circulating blood. Only a fraction of the
lipoprotein particles are “marginated” at the endothe-
lium, in contact with LPL [18]. This early phase of high
LPL activity in the circulating blood is reflected by
decreased levels of TG [5,19,20]. In agreement with
Akiba et al [21] and Katopodis et al [19] we found that
this early fall of plasma TG was less marked with the
LMW-heparin than with the UF-heparin. There was a
similar trend in the earlier study by Näsström et al [5]
b u ti nt h a tc a s et h ed i f f e r e n ce did not reach statistical
significance. The mechanism behind this is not immedi-
ately apparent. The higher levels of LPL activity in
blood at 40 min likely results in more rapid lipolysis of
lipoprotein triglycerides in the circulating blood. How-
ever, heparin also accelerates removal of partially lipo-
lyzed lipoprotein particles [3,22] and the heparin
preparations may differ in this regard, with UF-heparin
being more efficient than LMW-heparin.
With time after the administration of heparin, acceler-
ated transport of LPL from its natural sites of action to
the liver (where it is degraded [23]) leads to a temporary
depletion of the lipase [4,14]. Evidence for this in the
present study was the low amounts of LPL that could
be recruited into plasma by a second injection of a
heparin bolus late in the HD. This loss of LPL from the
system is presumably the main reason that plasma TG
tend to increase towards the end of the HD session and
during the hours thereafter [5]. This increase was more
marked with tinzaparin than with UF-heparin similar to
earlier studies with dalteparin [5] and with enoxaparin
[20]. This indicates that during the later part of the HD
and some hours thereafter, the system is more depleted
of LPL when using a LMW-heparin than when using
UF-heparin. The reduction of LPL at the endothelial
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Page 6 of 8sites (in the early phase of administration) and the loss
of active LPL (low levels during later part of HD) seems
to deplete ability of the patient to degrade triglycerides
into the energy resource of free fatty acids, during this
later phase of the HD. Apparently the anticoagulation
regimes do not result in a persistent depletion of LPL,
since the initial peak value after tinzaparin injection
remained unchanged throughout the 6 month study per-
iod. Hence, the system was able to fully recover between
dialyzes. Likewise, the temporarily decreased ability to
catabolize plasma TG, indicated by the rising plasma
TG levels, did not seem to carry over to a persistent
derangement of lipoprotein metabolism, since the
plasma lipid levels did not change during the 6 months
study period. Again, the system was apparently able to
fully recover between dialyses.
Elevated plasma lipid concentrations, particularly TG,
is a common concern in patients on chronic HD, since
cardiovascular diseases are the main causes of death in
patients on chronic HD. Therefore, the effects of differ-
ent heparin preparations on plasma lipid levels (mea-
sured between dialyses) are of interest. This has been
studied in a number of laboratories with somewhat vary-
ing results. It has been suggested that UF-heparin may
lead to aggravated hyperlipidemia during long term
treatment in patients on chronic HD [24,25]. In most
studies LMW-heparin during HD is associated with
decreases of TG and of total and LDL-cholesterol
[26-29]. These decreases appear to be more pronounced
in patients with hyperlipidemia [21,30-33], which is
common in patients with renal disease. More detailed
studies report a shift of LDL particles towards more
buoyant species away from the more atherogenic small
dense LDL subfractions [33]. These changes of the lipo-
protein profile with LMW-heparins may be regarded as
beneficial with respect to development of atherosclero-
sis. There are, however, also large, well-controlled stu-
dies that have found no consistent effect of LMW-
heparin on plasma lipids [34] and there are even studies
that report increased plasma lipid levels while on HD
with LMW-heparin [35]. In the present study we did
not observe any significant changes of the plasma lipid
levels studied, even when comparing values measured
during one year prior to the study and values measured
during 1 1/2-2 years after the study.
Conclusion
Our data suggest that repeated HD with UF-heparin or
tinzaparin does not exhaust the LPL-system.
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